Dr. David Chin is the Founder & CEO of Fibrosoft. He is a full time plastic surgeon in private practice with an interest in fibromatosiss and non surgical treatment in Dupuytren’s, Ledderhose and Peyronie’ disease. He is a Dean's List PhD Surgeon-scientist and to date, he has been the only person to analyse Dupuytren’s contracture tissue at cDNA microarray analysis using autologous contralateral normal palmar tissue and not using pool reference RNA as reference. Fibrosoft is a safe and efficacious novel formulation nonsurgical intralesional injection in the treatment of fibromatosis. The current gold standard, surgical excision, is painful and arduous recovery. Surgery in Ledderhose's disease worsens the condition. Successful treatment: In 270+ private patients have been treated with 30% improvement following the first injection. Safe with no serious adverse events (SAES) observed. Over 90% of patients return for further injections. He is seeking a licensee/VC funding to help exploit this attractive opportunity of over US$1.2B per annum. Australian and USA patents granted. •USA Patent No. 12,280,095 on 22 April 2025. •Granted Australian Patent No. 2022335159 •Australian Divisional Application No. 2024200488 •European Application No. 22859663.1 •Under accelerated prosecution •Projected Expiry Date:   25 August 2042- (* Brisbane Olympic City 2032).